Critical First Step: Confirm Active Congenital CMV Infection
A positive CMV IgG alone in a newborn does NOT confirm congenital CMV infection—it only indicates maternal antibody transfer. You must immediately obtain urine or saliva CMV PCR within 21 days of life to diagnose true congenital infection 1. IgG positivity is expected in most infants born to CMV-seropositive mothers and is clinically meaningless without virologic confirmation.
Immediate Diagnostic Confirmation
- Obtain urine or saliva CMV PCR within 21 days of life (ideally within 2 weeks) 2, 1
- This is the ONLY way to distinguish congenital infection from passive maternal antibody transfer
- Testing after 21 days cannot reliably differentiate congenital from postnatal infection
If CMV PCR is Positive: Comprehensive Assessment for Symptomatic Disease
A symmetrical SGA infant with confirmed congenital CMV requires systematic evaluation for end-organ involvement, as this determines treatment eligibility and long-term prognosis.
Neurologic Assessment
- Head circumference measurement (microcephaly is a key symptomatic feature)
- Cranial ultrasound or brain MRI looking for:
Auditory Assessment
- Comprehensive auditory brainstem response (ABR) testing at baseline
- Standard newborn hearing screens miss 43% of infants with cCMV who will develop hearing loss 4
- Serial audiologic follow-up is mandatory even if initial testing is normal, as hearing loss can be late-onset or progressive—occurring in 11.3% of asymptomatic infants by 12 months and up to 25% by 18 years 4
Ophthalmologic Assessment
- Dilated fundoscopic examination by ophthalmology
- Look for chorioretinitis, optic atrophy, or other retinal abnormalities 2, 1
Laboratory Assessment
- Complete blood count (thrombocytopenia, anemia)
- Liver function tests (transaminitis, conjugated hyperbilirubinemia)
- Note: Absence of cytopenia or transaminitis does NOT exclude symptomatic disease 2
Clinical Context: Why This Matters
The symmetrical SGA pattern raises concern for early gestational infection. While SGA alone has low diagnostic yield for cCMV (0.54-3.3% positivity rate) 5, 3, 6, if infection is confirmed, 10-15% will have symptomatic disease at birth, with over 50% of symptomatic infants developing long-term disabilities 4. The combination of SGA with other findings (microcephaly, intracranial calcifications, failed hearing screen) dramatically increases the likelihood of symptomatic disease requiring treatment.
Treatment Considerations
Symptomatic infants with CNS involvement (including isolated microcephaly or intracranial abnormalities) or hearing loss should receive valganciclovir therapy, which reduces hearing loss in 5 out of 6 treated babies and improves neurodevelopmental outcomes 2, 1. Treatment must be initiated within the first month of life for maximum benefit.
Long-Term Monitoring
All infants with confirmed congenital CMV—even if asymptomatic—require:
- Serial audiology assessments at minimum through 2 years of age (or longer based on disease status) 1
- Neurodevelopmental follow-up
- Ophthalmology surveillance
Critical pitfall: Even "asymptomatic" infants remain at 20% risk for developing SNHL in childhood, with emerging data showing nearly half develop gaze, balance, and vestibular disorders 4. Do not discharge from follow-up based on normal initial assessments.